Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial-Reference-Cited by-同舟云学术

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial

Published:2017-09-12 Issue:3 Volume:233 Page:2572-2580
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J Cell Physiol

Author:

Terrenato Irene¹^ORCID,Sperati Francesca¹,Musicco Felice²,Pozzi Anna F.³,di Turi Annunziata⁴,Caterino Mauro⁵,de Lutio di Castelguidone Elisabetta⁶,Setola Sergio V.⁶,Bellomi Massimo⁷⁸,Neumaier Carlo E.⁹,Conti Laura¹⁰,Cigliana Giovanni¹⁰,Merola Roberta¹⁰,Antenucci Anna¹⁰,Orlandi Giulia¹⁰,Giordano Antonio¹¹¹²,Barba Maddalena⁴¹³,Canitano Stefano⁵

Affiliation:

1. Biostatistic Unit; Regina Elena National Cancer Institute; Rome Italy

2. Service of Pharmacovigilance; Regina Elena National Cancer Institute; Rome Italy

3. AUSL di Bologna; Bologna Italy

4. Scientific Direction; Regina Elena National Cancer Institute; Rome Italy

5. Department of Diagnostic Imaging; Regina Elena National Cancer Institute; Rome Italy

6. Department of Diagnostic Imaging, Radiant and Metabolic Therapy; Istituto Nazionale Tumori IRCCS Fondazione Pascale; Naples Italy

7. Department of Medical Imaging and Radiation Sciences; European Institute of Oncology; Milan Italy

8. Department of Oncology and Hematology-Oncology; University of Milan; Milan Italy

9. Diagnostic Imaging and Senology; IRCCS-A.O.U., San Martino-IST; Genoa Italy

10. Departement of Clinical Patology; Regina Elena National Cancer Institute; Rome Italy

11. Department of Medicine; Surgery and Neuroscience; University of Siena and Istituto Toscano Tumori (ITT); Siena Italy

12. Department of Biology; Sbarro Institute for Cancer Research and Molecular Medicine; College of Science and Technology; Temple University; Philadelphia Pennsylvania

13. Division of Medical Oncology 2; Regina Elena National Cancer Institute; Rome Italy

Funder

Agenzia Italiana del Farmaco, Ministero della Salute

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Reference36 articles.

1. Trends in the incidence of acute kidney injury in patients hospitalized with acute myocardial infarction;Amin;Archives of Internal Medicine,2012

2. Iodixanol: Risk of subsequent contrast nephropathy in cancer patients with underlying renal insufficiency undergoing diagnostic computed tomography examinations;Cheruvu;Journal of Computer Assisted Tomography,2007

3. Incidence of acute kidney injury in cancer patients: A Danish population-based cohort study;Christiansen;European Journal of Internal Medicine,2011

4. Incidence of contrast-induced nephropathy in hospitalised patients with cancer;Cicin;European Radiology,2014

5. Transcrptome-based analysis of molecular pathways for clusterin fuctions in kidney cells;Dairi;Journal of Cellular Physiology,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevention of post-contrast kidney injury in patients with cancer;Drugs in Context;2024-03-14

2. Iodixanol as a New Contrast Agent for Cyanoacrylate Embolization: A Preliminary In Vivo Swine Study;Biomedicines;2023-11-29

3. Bismuth chelate as a contrast agent for X-ray computed tomography;Journal of Nanobiotechnology;2020-08-06

4. Profilaxis de la lesión renal aguda poscontraste (LRA-PC). Actualización según la guía clínica ESUR 10.0 y revisión crítica;Radiología;2020-07

5. Prophylaxis against postcontrast acute kidney injury (PC-AKI): Updates in the ESUR guidelines 10.0 and critical review;Radiología (English Edition);2020-07